Article

Quality of vision improves with wavefront-guided system

Barcelona, Spain—The Zyoptix system (Bausch & Lomb) for wavefront-guided ablation is as effective as the conventional Planoscan (Bausch & Lomb) LASIK procedure in the correction of low to moderate myopia. Zyoptix, however, is advantageous because it induces less total, higher-order, and third-order aberrations. In addition, the quality of vision under low illumination and with low-contrast objects is better than that achieved with Planoscan, according to Jorge Castanera, MD, and Carlos Rios, OC.

The investigators conducted a study at the Instituto de OftalmologíCastanera, Barcelona, Spain, in which they evaluated the efficacy and safety of the two systems. The 25 study patients were treated in one eye with the Zyoptix system with Zylink 2.33 software and in the other eye with Planoscan.

"We used very strict inclusion criteria so that both eyes were equal. We then selected randomly one eye for Zyoptix treatment and the contralateral eye served as control and was treated with Planoscan," explained Dr. Castanera, medical director, Instituto de Oftalmología Castanera.

In the eyes treated with Planoscan, the mean spherical equivalent was -4.14 ± 1.91 D (range, -1.13 to -9 D), the sphere was -3.90 ± 1.82 D (range, -1 to -8.5 D), and the cylinder was -0.48 ± 0.44 D (range, 0 to -1.5 D).

In the eyes treated with Zyoptix, the mean spherical equivalent was -4.15 ± 1.77 D (range, -1.5 to -9 D), the sphere was -3.85 ± 1.66 D (range, -1.5 to -8.5 D), and the cylinder was -0.59 ± 0.44 D (range, 0 to -1.75 D). Dr. Castanera reported that the results were analyzed for up to 3 months after the treatment and that there was no difference in the refractive results or in the uncorrected visual acuity between the two groups.

The spherical equivalent was very stable and similar in the two groups at 1 week, 1 month, and 3 months after the surgery, 0.13, -0.01, and -0.09 D, respectively, in the eyes treated with Zyoptix and -0.24, -0.08, and -0.18 D in the eyes treated with Planoscan. The uncorrected visual acuity levels in LogMAR units at 1 week, 1 month, and 3 months in the eyes treated with Zyoptix were -0.08, -0.1, and -0.09, respectively. In the eyes treated with Planoscan the respective values were 0.24, -0.08, and -0.18.

Dr. Castanera also reported that the eyes treated with Zyoptix had significantly less total and higher-order aberrations and less third-order aberrations. Both comparisons reached statistical significance at the 3-month time point (p = 0.002 for total higher-order aberrations and p = 0.0003 for third-order aberrations).

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) ASCRS 2025: Advancing vitreous care with Inder Paul Singh, MD
(Image credit: Ophthalmology Times) The Residency Report: Study provides new insights into USH2A target end points
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
(Image credit: Ophthalmology Times) ASCRS 2025: Gregory Moloney, FRANZO, FRCSC, on rotational stability
© 2025 MJH Life Sciences

All rights reserved.